$BEAT

HeartBeam (NASDAQ: BEAT) presented pilot study results comparing its 3D ECG technology to standard 12-lead ECG for detecting acute coronary syndrome. The study, ALIGN-ACS, will inform the design of HeartBeam’s planned U.S. pivotal study. HeartBeam received FDA Breakthrough Device Designation for heart attack assessment and was accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP). Results will be presented at TCT 2026.

HeartBeam (NASDAQ: BEAT) announced its heart attack assessment technology was accepted into the FDA's TAP Pilot program, following a Breakthrough Device Designation earlier this month. The TAP program offers regulatory support and early engagement with payers. The company aims to begin patient enrollment for a pivotal study in Q1 2027, pending FDA alignment. The HeartBeam System is currently cleared for arrhythmia assessment but not for heart attack detection.

HeartBeam Inc. (NASDAQ: BEAT) completed enrollment in its HEADSTART-ACS study, evaluating its 3D ECG system for heart attack detection, ahead of schedule. The study, conducted with Indonesia's National Cardiovascular Center, enrolled 486 patients. Results are expected in 2027. The company has over 600 patients in its heart attack detection studies, ahead of its U.S. pivotal study planned for Q1 2027.

HeartBeam (BEAT) joined the EU EXIT-CVD consortium and will lead the HEART-CHECK study to evaluate its at-home ECG system in high-risk post-ACS patients. The company's contribution is in-kind, and the device's use for heart attack assessment is investigational.

U.S. stocks rose midday, with the Dow up 0.20% and NASDAQ up 0.84%. ISM services PMI fell to 54.9 in September. Columbus Acquisition (SAIQ) surged 286% post-SPAC merger, Vaxcyte (PCVX) up 40% on trial results, and HeartBeam (BEAT) up 70% after FDA designation. Camping World (CWH) down 10% on EBITDA guidance cut.

HeartBeam (BEAT) received FDA Breakthrough Device Designation for its HeartBeam System, which assesses potential heart attacks at home. The system uses 3D ECG technology to enable remote diagnosis. The designation accelerates development and regulatory review. BEAT stock rose 3.72% on October 2, 2026, and was up 97.42% in pre-market trading.

HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 14, 2026, HeartBeam, Inc. (the “Company”), entered into an At-The-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Titan Partners Securities LLC, as sales agent, pursuant to which the Company may

Heartbeam Inc shares fell 1.7% after hours to $0.58 after the company reported Q2 2026 results. Net loss was $0.10 per share versus a $0.09 estimate, with operating expenses of $5.1M. Heartbeam lowered full-year 2026 cash outflow guidance and said ALIGN-ACS pilot enrollment was completed early.

HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On July 31, 2026, HeartBeam, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) virtually, via live webcast. As of the close of business on June 5, 2026, the record date for the Annual M

HeartBeam Inc. (BEAT) said the U.S. Patent Office allowed a new patent covering acoustic sensing and thoracic impedance measurement for its cable-free ECG device. The company says the device can act as a digital stethoscope and monitor chest fluid buildup for heart failure management. BEAT shares were about $0.50, down 11.91%, near a 52-week low.